An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Males and females, ≥ 18 years of age
• Diagnosis of mild to moderate asthma for at least 12 months
• Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal
• Airway reversibility ≥ 12% and 200 mL improvement in FEV1
• Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment
• Willing and able to comply with all study requirements and procedures
Locations
United States
Kansas
The University of Kansas Medical Center
RECRUITING
Kansas City
Contact Information
Primary
Celldex Therapeutics
clinicaltrials@celldex.com
844-723-9363
Time Frame
Start Date: 2026-02
Estimated Completion Date: 2027-03
Participants
Target number of participants: 12
Treatments
Experimental: CDX-622
Eligible participants will receive a single dose
Related Therapeutic Areas
Sponsors
Leads: Celldex Therapeutics